Rosuvastatin-Cyclosporine Transporter DDI Case Study

Why This Interaction Is a Useful Case

Rosuvastatin is subject to transporter-mediated disposition, and cyclosporine inhibits transport processes relevant to its uptake and efflux. The interaction is therefore a useful test of whether a model represents more than a single “transporter inhibition” switch. Hepatic uptake, hepatic efflux, and intestinal efflux act at different locations; their effects on plasma exposure and on hepatocyte concentrations need not be identical.

Product labeling reports that cyclosporine coadministration increases rosuvastatin exposure substantially: rosuvastatin AUC is about 7-fold higher and \(C_{\max}\) about 11-fold higher. Those clinical values provide a reference for model evaluation, not proof that a particular transporter mechanism or parameter set is correct. The calculations below use explicitly hypothetical model inputs and are not a reconstruction of a clinical study.

Representing the Transporter Pathways

OATP1B1 and OATP1B3 mediate hepatic uptake of rosuvastatin. Inhibiting uptake can reduce hepatic extraction and raise plasma concentrations, while also reducing drug entry into hepatocytes. BCRP is relevant to efflux, including intestinal efflux that can limit absorption and hepatic efflux that can contribute to drug movement out of hepatocytes. Inhibiting intestinal BCRP can increase the fraction reaching the systemic circulation. Inhibiting hepatic efflux can change intracellular retention and the effective hepatic elimination pathway.

A detailed PBPK model can represent these processes in separate organs and compartments. To make the case calculation transparent, use a reduced model with three aggregate quantities: \(R_F\), the ratio of oral bioavailability with versus without cyclosporine; \(f_H\), the baseline fraction of total systemic clearance attributable to an uptake-dependent hepatic route; and \(q_u\) and \(r_e\), the remaining fractions of uptake activity and effective intracellular exit, respectively, during inhibition. Each remaining fraction is between 0 and 1. Here, \(r_e\) represents the net effect of hepatic efflux inhibition on that route; it is a simplification, not a measured BCRP activity.

The model assumes linear pharmacokinetics over the dose range, the same dose in both conditions, and a matched comparison in which other determinants of bioavailability and clearance are unchanged. It also assumes that the uptake-dependent clearance route can be approximated as sequential: drug must enter the liver and then undergo effective intracellular removal. Under this reduction, the clearance ratio is:

The term \(1-f_H\) is the clearance fraction assumed unaffected by this hepatic route. The term \(f_Hq_ur_e\) is the residual uptake-dependent route when both uptake and effective intracellular exit may be inhibited. If a particular model represents hepatic efflux in a different way, its clearance expression should be derived from that model’s compartment equations rather than assumed to equal this one.

Deriving the Exposure-Ratio Calculation

For linear pharmacokinetics after an oral dose, AUC is proportional to dose multiplied by bioavailability and divided by systemic clearance. With the same dose in both conditions, the dose cancels from the ratio. Thus:

This derivation explains why a change in oral availability and a change in systemic clearance both matter. An intestinal BCRP effect can be represented in \(R_F\), while the simplified hepatic uptake-efflux route is represented in the clearance denominator. The formula does not imply that all BCRP effects can be reduced to one scalar; it is a compact way to organize a screening calculation.

Separating the Contributions and the Endpoints

A joint prediction can conceal which mechanism drives the result. Counterfactual calculations, in which one pathway is changed at a time, help interpret the reduced model. They are diagnostic decompositions, not necessarily independently observable clinical effects.

Comparing With Clinical Evidence and Evaluating Uncertainty

The clinical reference is an approximate 7-fold AUC increase and a larger, roughly 11-fold \(C_{\max}\) increase. The hypothetical 7.09-fold AUC prediction is compatible in magnitude with the AUC reference, but it does not automatically predict \(C_{\max}\). Peak concentration depends on absorption rate, distribution, and sampling-time behavior as well as on total exposure. A model that matches AUC but misses \(C_{\max}\) may have an inadequate absorption or time-course representation even if its overall clearance change is plausible.

Uncertain transporter abundance, inhibition potency, site-specific inhibitor concentration, and the fraction of clearance routed through hepatic uptake can produce substantial uncertainty. A scenario envelope is one transparent way to show sensitivity; it is not a confidence interval unless a probability model and inferential procedure justify that interpretation.

Diagnostics, Alternatives, and Limitations

Before interpreting a prediction, check whether the model’s structure and inputs support the calculation. Useful diagnostics include:

• Pathway consistency: confirm that hepatic uptake and intestinal or hepatic efflux are assigned to the correct compartments, and that the same process is not counted twice.
• Parameter plausibility: inspect whether residual activity values are compatible with the inhibition data and inhibitor concentrations at the transporter site.
• Mass balance and limiting cases: with no inhibition, \(q_u=r_e=R_F=1\), the predicted ratio should equal 1. As uptake-dependent clearance becomes dominant and residual uptake approaches zero, the predicted clearance may become very small; implausibly extreme ratios can reveal an over-sensitive or incomplete model.
• Endpoint agreement: compare predicted and observed AUC and \(C_{\max}\) separately. AUC agreement does not guarantee an adequate prediction of the concentration-time profile or peak.
• Uncertainty sensitivity: identify whether the result is driven by one poorly known input, such as \(f_H\) or \(R_F\), rather than presenting only a single precise ratio.

The reduced calculation is useful for organizing mechanisms and screening parameter combinations. A full PBPK model is preferable when organ-specific concentrations, time-varying inhibition, absorption, distribution, or hepatic return and biliary processes materially affect the prediction. A clinical empirical comparison can establish the observed magnitude under the conditions studied, but by itself cannot separate intestinal from hepatic contributions. Conversely, a mechanistic model can explore those contributions, but its explanation depends on structural assumptions and input quality.

A key limitation is that the simplified clearance expression treats hepatic uptake and effective intracellular removal as sequential factors. Real transport and metabolism may involve parallel routes, basolateral return, multiple transporters, and concentration-dependent processes. The scalar \(r_e\) cannot substitute for explicitly representing those processes when they are important. Further, an AUC ratio is not a direct measurement of transporter inhibition, and agreement with one clinical interaction does not guarantee performance for another substrate or inhibitor.

Common Mistake

Wrong reasoning: “The model predicts a 7-fold AUC increase, matching the clinical result, so the OATP and BCRP mechanisms and their parameters are confirmed.” This overstates what one matched summary can establish. The same AUC ratio can arise from different combinations of bioavailability and clearance changes, and a model may still miss \(C_{\max}\), tissue exposure, or the underlying time course.

Correction: Treat the clinical comparison as a constraint on the combined prediction. Examine pathway-specific assumptions, sensitivity to uncertain parameters, other exposure endpoints, and whether the model reproduces the relevant concentration-time behavior before drawing mechanistic conclusions.